Study guide

4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology

Key Takeaways Explain This Topic AI

KDIGO criteria define AKI by a serum creatinine increase ≥ 26.5 µmol/L in 48h, a creatinine increase ≥ 1.5x baseline within 7 days, or urine output < 0.5 mL/kg/h for 6 hours.

Prerenal AKI features FENa < 1% (FeUrea < 35% on diuretics), urine Na < 20 mmol/L, and hyaline casts; Intrinsic ATN features FENa > 2%, urine Na > 40 mmol/L, and muddy brown granular casts.

Nephrotic syndrome presents with heavy proteinuria (> 3.5 g/day or UACR > 220 mg/mmol), hypoalbuminemia (< 30 g/L), edema, and hyperlipidemia; Nephritic syndrome presents with dysmorphic RBCs, RBC casts, hypertension, oliguria, and mild-moderate proteinuria.

CKD management focuses on delaying progression using ACE inhibitors or ARBs for proteinuria (UACR > 3.0 mg/mmol) and SGLT2 inhibitors (empagliflozin, dapagliflozin) for eGFR ≥ 20 mL/min/1.73m² regardless of diabetes status.

Urgent hemodialysis indications follow the AEIOU mnemonic: Acidosis (pH < 7.10), Electrolytes (refractory K+ > 6.5 mmol/L), Intoxications (SLIME), Overload (refractory pulmonary edema), Uremia (encephalopathy, pericarditis, bleeding).

Last updated: July 2026

  • 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology
  • KDIGO Staging & Etiology Differentiation of AKI

According to KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, Acute Kidney Injury (AKI) is defined by meeting any of the following:

Increase in serum creatinine by ≥ 26.5 µmol/L within 48 hours .

Increase in serum creatinine to ≥ 1.5 times baseline within 7 days .

Urine volume < 0.5 mL/kg/h for 6 consecutive hours .

KDIGO AKI Staging Grid

  • Stage Serum Creatinine Threshold Urine Output Threshold
  • Stage 1 1.5 – 1.9x baseline OR increase ≥ 26.5 µmol/L < 0.5 mL/kg/h for 6 – 12 hours
  • Stage 2 2.0 – 2.9x baseline < 0.5 mL/kg/h for ≥ 12 hours

Stage 3 3.0x baseline OR creatinine ≥ 353.6 µmol/L OR initiation of RRT < 0.3 mL/kg/h for ≥ 24 hours OR Anuria for ≥ 12 hours

Etiological Classification & Diagnostic Indices

Feature Prerenal AKI Intrinsic AKI (ATN) Intrinsic AKI (AIN) Postrenal AKI

Primary Cause Hypovolemia, HF, Sepsis, ACEi/ARB + NSAIDs Ischemia, Contrast, Aminoglycosides, Rhabdomyolysis Drug hypersensitivity (PPIs, NSAIDs, Penicillins) BPH, Prostate Cancer, Bilateral Calculi, Neurogenic Bladder

  • BUN:Cr Ratio > 80:1 (mmol:mmol) < 40:1 < 40:1 Variable
  • FENa (%) < 1% (FeUrea < 35%) > 2% > 1% Variable
  • Urine Sodium < 20 mmol/L > 40 mmol/L > 20 mmol/L Variable
  • Urine Osmolality > 500 mOsm/kg < 350 mOsm/kg Variable < 350 mOsm/kg
  • Urinalysis / Casts Hyaline casts Muddy brown granular casts WBC casts, Eosinophiluria Normal / RBCs / Pyuria
  • Renal Ultrasound Normal Normal Normal / Enlarged Hydronephrosis / Hydroureter

Formula for Fractional Excretion of Sodium (FENa) : FENa (%) = [(Urine Na x Serum Cr) / (Serum Na x Urine Cr)] x 100. In patients taking loop diuretics, FeUrea (< 35%) is more accurate than FENa.

  • Glomerular Diseases: Nephrotic vs Nephritic Syndromes
  • Nephrotic vs Nephritic Syndrome Comparison

Diagnostic Parameter Nephrotic Syndrome Nephritic Syndrome

Primary Pathology Podocyte damage -> breakdown of filtration barrier Glomerular inflammation -> cell proliferation & capillary damage

  • Clinical Triad Anasarca, Heavy Proteinuria, Hypoalbuminemia Hematuria, Oliguria, Hypertension
  • Proteinuria Level > 3.5 g/24h (UACR > 220 mg/mmol) Mild to Moderate (< 3.5 g/24h)
  • Serum Albumin Hypoalbuminemia (< 30 g/L) Normal or mildly decreased
  • Urine Sediment Oval fat bodies, fatty casts, "Maltese cross" Dysmorphic RBCs, RBC Casts

Major Complications Hypercoagulability (loss of antithrombin III -> RVT/DVT), Hyperlipidemia AKI, Hypertensive Emergency, Fluid Overload

Key Glomerular Etiologies

Minimal Change Disease : Most common cause of nephrotic syndrome in children. Normal glomeruli on light microscopy; podocyte effacement on electron microscopy. Highly responsive to corticosteroids (prednisone).

Membranous Nephropathy : Most common primary nephrotic syndrome in Caucasian adults. Associated with anti-PLA2R antibodies , HBV, solid tumors, and NSAIDs. Thickened basement membrane with "spike and dome" pattern on silver stain.

Diabetic Nephropathy : Nodular glomerulosclerosis ( Kimmelstiel-Wilson nodules ), mesangial expansion, and progressive albuminuria.

Post-Streptococcal GN (PSGN) : Nephritic syndrome presenting 1–3 WEEKS AFTER group A beta-hemolytic streptococcal pharyngitis or impetigo. Characterized by LOW serum C3 complement and lumpy-bumpy subepithelial deposits.

IgA Nephropathy (Berger Disease) : Most common primary GN worldwide. Young adult presenting 1–2 DAYS AFTER an upper respiratory infection (synpharyngitic hematuria). Characterized by NORMAL serum C3 complement and mesangial IgA deposition.

ANCA Vasculitis (GPA / Wegener) : PR3-ANCA / c-ANCA positive. Triad of upper respiratory sinus lesions, lower respiratory pulmonary nodules/hemoptysis, and pauci-immune crescentic GN.

Anti-GBM (Goodpasture) Disease : Autoantibodies against alpha-3 chain of type IV collagen causing pulmonary hemorrhage PLUS Rapidly Progressive GN. Linear IgG deposition along glomerular basement membrane.

Chronic Kidney Disease (CKD) Staging & Progression Delay

CKD is defined by kidney damage or eGFR < 60 mL/min/1.73m² present for > 3 months .

KDIGO Staging Matrix

eGFR Categories : G1 (≥ 90), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29), G5 (< 15 or Dialysis).

Albuminuria Categories : A1 (UACR < 3.0 mg/mmol - Normal/Mild), A2 (UACR 3.0–30.0 mg/mmol - Moderate), A3 (UACR > 30.0 mg/mmol - Severe).

Evidence-Based Interventions to Slow CKD Progression

RAAS Blockade (ACEi or ARB) : Titrated to maximum tolerated dose in all patients with CKD and hypertension or albuminuria (UACR > 3.0 mg/mmol). Reduces intraglomerular pressure by dilating efferent arterioles. Expect up to a 30% rise in serum creatinine upon initiation; do NOT discontinue unless creatinine rises > 30% or refractory hyperkalemia develops .

SGLT2 Inhibitors (Empagliflozin, Dapagliflozin) : Indicated for all CKD patients with eGFR ≥ 20 mL/min/1.73m² and UACR > 3.0 mg/mmol, regardless of diabetes status . Reduces hyperfiltration, slows eGFR decline, and reduces ESKD/death.

Blood Pressure Control : Target BP < 120/80 mmHg per KDIGO 2021 guidelines using standardized measurement.

Lifestyle Modifications : Dietary sodium restriction (< 2.0 g/day), protein intake 0.8 g/kg/day, avoidance of nephrotoxins (NSAIDs, IV contrast).

Indications for Urgent Hemodialysis (AEIOU Mnemonic)

  • Letter Emergency Indication Clinical Diagnostic Threshold
  • A Acidosis Severe refractory metabolic acidosis with pH < 7.10 despite medical management
  • E Electrolytes Severe refractory hyperkalemia with K+ > 6.5 mmol/L or ECG changes persistent despite therapy

I Intoxications Poisoning with dialyzable toxins ( SLIME : Salicylates, Lithium, Isopropanol, Methanol, Ethylene glycol)

  • O Overload Refractory volume overload / Acute pulmonary edema non-responsive to high-dose IV loop diuretics
  • U Uremia Symptomatic uremia: Uremic Pericarditis , uremic encephalopathy/asterixis, uremic bleeding

Important

MCCQE1 High-Yield Distinction: IgA Nephropathy vs Post-Streptococcal GN • IgA Nephropathy (Berger Disease) : Recurrent gross hematuria occurring CONCURRENTLY (1–2 days after) an upper respiratory tract infection. Serum C3 complement levels are NORMAL .

• Post-Streptococcal GN : Hematuria occurring 1–3 WEEKS AFTER a streptococcal pharyngeal or skin infection. Serum C3 complement levels are LOW (hypocomplementemia).

Loading diagram... Algorithmic Differential Diagnosis of Acute Kidney Injury (AKI)